Phase 2 N=58 Randomized Triple-blind Treatment

Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis

Ambulatory IPF

Bottom Line

View on ClinicalTrials.gov: NCT01969409 ↗

Enrolled (actual)

Serious AEs

24.1%

Results posted

Nov 2021

Primary outcome: Primary: Autoantibodies to Human Epidermoid (HEp)-2 Cells — 288; 177 titer

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Rituximab (Drug); Placebo (Drug)
Age: Adult, Older Adult · 50+ yrs
Sex: All
Sponsor: University of Alabama at Birmingham
Primary completion: Jan 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Autoantibodies to Human Epidermoid (HEp)-2 Cells	288; 177	—
SECONDARY Changes in Anti-Heat Shock Protein 70 (HSP70) Autoantibodies	1.0; 0.83	—
SECONDARY Changes in Forced Vital Capacity (FVC)	2.6; 2.5	—
SECONDARY Number of Adverse Events (AE)	7; 12	—
SECONDARY Number of Acute Exacerbations	1; 2	—
SECONDARY Absolute Survival Percentage	93; 93	—
SECONDARY Transplant-Free Survival	89; 90	—
SECONDARY Hospitalizations	6; 12	—

Summary

Recent research studies have suggested that proteins called antibodies that are produced by the immune system might be involved in the lung damage of idiopathic pulmonary fibrosis (IPF). Antibodies produced by the immune system normal help to fight infections by attacking bacteria and viruses without harming our own tissues. In patients with IPF, there is evidence that certain antibodies (called autoantibodies) attack the lung and contributes to the injury and scarring that occurs in IPF. Our recent studies have found that many IPF patients appear to have excessive autoantibody levels in blood and lungs that might make their disease worse. Rituximab is a medication approved by the Food and Drug Administration (FDA) for the treatment of autoantibody diseases such as rheumatoid arthritis. Rituximab works by destroying B cells, a type of white blood cell, called a B-lymphocyte, which produce autoantibodies. In this research study, rituximab will be given into a vein to reduce the autoantibody levels that we believe might be contributing to the lung damage in IPF. This study is being conducted to determine if rituximab provides beneficial effects for IPF patients by decreasing further lung injury.

Eligibility Criteria

Inclusion Criteria

Ambulatory patients with a diagnosis of IPF, not established >5 years from the enrollment date, that fulfills American Thoracic Society (ATS)/European Thoracic Society (ETS) Consensus Criteria.

Ability and willingness to give informed consent. Presence of autoantibodies against Hepatoma-2 (HEp-2) cells, the assay for the primary endpoint.

Age 50-85 y.o.

Exclusion Criteria

Diagnoses of current infection, proven or suspected by participating physicians based upon their clinical assessments.

Presence of active hepatitis B or C, or HIV infection. Presence of positive CONVENTIONAL autoimmune serologic tests, e.g., Antinuclear Antibodies (ANA), Rheumatoid Factor (RF), Anti-Ro, Anti-LA, Anti-Ribonucleoprotein Antibodies (RNP), Anti-Jo-1.

History of reaction to murine-derived products or any of the trial medications, or prior exposures to human-murine chimeric antibodies.

Malignancy, excluding basal or squamous cell skin cancer and low-risk prostate cancer, defined as stage T1 or T2a with Prostate-Specific Antigen (PSA) less than 10 ng/dl.

Unwillingness to complete post-treatment surveillance for 9 months. Diagnosis of major morbidities (aside from IPF) expected to interfere with subjects' study participation for 9 months.

Treatment for >5 days within the preceding month with >10 mg. prednisone (or equivalent corticosteroid) or any treatment during the preceding month with a potent cellular immunosuppressant (e.g., cyclophosphamide, methotrexate, mycophenolate, azathioprine, calcineurin inhibitors, etc.).

Uncontrolled diabetes or hypertension that preclude safe treatment with methylprednisolone.

Concurrent participation in other experimental trials.

Pregnancy or unwillingness to use contraception during the duration of the study among female participants with child-bearing potential.

Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) <70% of predicted values.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01969409). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.